Neurobiology of Brain Disorders
Biological Basis of Neurological and Psychiatric Disorders
- 2nd Edition - May 19, 2022
- Editors: Michael J. Zigmond, Clayton A. Wiley, Marie-Françoise Chesselet
- Language: English
- Hardback ISBN:9 7 8 - 0 - 3 2 3 - 8 5 6 5 4 - 6
- eBook ISBN:9 7 8 - 0 - 3 2 3 - 8 9 8 2 5 - 6
Neurobiology of Brain Disorders: Biological Basis of Neurological and Psychiatric Disorders, Second Edition provides basic scientists a comprehensive overview of neurologi… Read more
Purchase options
Institutional subscription on ScienceDirect
Request a sales quoteNeurobiology of Brain Disorders: Biological Basis of Neurological and Psychiatric Disorders, Second Edition provides basic scientists a comprehensive overview of neurological and neuropsychiatric disease. This book links basic, translational, and clinical research, covering the genetic, developmental, molecular and cellular mechanisms underlying all major categories of brain disorders. It offers students, postdoctoral fellows, and researchers in diverse fields of neuroscience, neurobiology, neurology, and psychiatry the tools they need to obtain a basic background in the major neurological and psychiatric diseases. Topics include developmental, autoimmune, central, and peripheral neurodegeneration, infectious diseases, and diseases of higher function.
Organized by individual disorder, each chapter includes coverage of the clinical condition, diagnosis, treatment, underlying mechanisms, relevant basic and translational research, and key unanswered questions. This volume reflects progress in the field since publication of the first edition, with fully updated chapters, and new chapters on isolation, aging, global diseases, vascular diseases, and toxic/metabolic disease. New disorder coverage includes fibromyalgia, chronic fatigue, Restless Legs Syndrome, myasthenia gravis, and more.
- Links basic, translational and clinical research on disorders of the nervous system
- Covers a vast array of neurological and psychiatric disorders, including Down syndrome, autism, muscular dystrophy, diabetes, TBI, Parkinson's, Huntington's, Alzheimer's, OCD, PTSD, schizophrenia, depression and pain
- Features new chapters on the effects of aging and isolation on brain health
- Expands coverage on disorders, including new chapters on fibromyalgia, chronic fatigue, and restless legs syndrome
- Features in-text summary points, special feature boxes and research questions
- Cover image
- Title page
- Table of Contents
- Copyright
- Dedication
- Contributors
- Preface
- Acknowledgments
- Thoughts on teaching about the neurobiology of diseases
- Potential audiences for teaching
- How to provide the instruction?
- How to divide topics?
- Special cases
- How to present yourself
- Conclusions
- Section I. Introduction
- Chapter 1. Introduction
- Chapter 2. Developmental disabilities and metabolic disorders
- Introduction
- Development
- Functional development
- Etiology
- Techniques
- Principles of management
- Practice guidelines
- Conclusion
- Questions for further research
- Chapter 3. Attention-deficit/hyperactivity disorder
- Introduction
- Clinical description
- Neuroimaging studies
- Advances in genetic research
- Brain imaging genetics in ADHD
- Modeling ADHD in animal models and cellular systems
- Conclusion
- Questions for further research
- Chapter 4. Down syndrome: a model for chromosome abnormalities
- Introduction
- Down syndrome
- Mouse models of Down syndrome
- Changes in cognition in Down syndrome
- Cognition in DS
- Development of pharmacotherapy in Down syndrome
- Conclusion and questions for the future of research and treatment for DS
- Chapter 5. Autism spectrum disorder
- Introduction
- History
- Clinical features
- Definition and classification
- Epidemiology
- Natural history
- Differential diagnosis
- Assessment
- Neuropsychological profile/cognitive functioning
- Neurobiology
- Neuroimaging
- Neurophysiology
- Neuropathology
- Neurochemistry
- Genetic and environmental risk factors
- Animal models of ASD
- Inducible pluripotent stem cells (iPSCs)
- Treatment
- Future directions
- Chapter 6. Rett syndrome: from the involved gene(s) to treatment
- Introduction
- Clinical features of Rett syndrome and other MECP2-related disorders
- Diagnosis and clinical management of Rett syndrome
- Genetics of Rett syndrome: the MECP2 gene, pathogenic mutations, and phenotypic outcomes
- Mecp2 mouse models recapitulating human MECP2-related pathologies
- MeCP2 expression during brain development: role in neuronal maturation and maintenance of the mature state
- Neuromorphological and neurophysiological consequences of MeCP2 dysfunction
- Rett syndrome: not solely a neuronal disease
- MeCP2: a multifunctional protein whose pathogenic mechanisms remain unsolved
- MeCP2 research: from bench to bedside
- Conclusion and future challenges
- Chapter 7. Fragile X-associated disorders
- Introduction
- RNA toxicity in premutation carriers
- Fragile X syndrome
- Targeted treatments for fragile X syndrome
- Clinical manifestations of the fragile X premutation
- Animal and cellular models
- Conclusion
- Areas for future research
- Section II. Diseases of the peripheral nervous system
- Chapter 8. Introduction
- Chapter 9. Myasthenia gravis
- Introduction
- Immunopathogenesis
- Neuromuscular transmission defect
- Animal models of myasthenia gravis
- Epidemiology and genetics
- Clinical phenotype
- Treatment
- Conclusion
- Chapter 10. Muscular dystrophy
- Introduction
- Pathophysiology and genetics
- Epidemiology
- Clinical manifestations
- Diagnosis
- Genetic counseling
- Cellular and animal models
- Treatment and outcomes
- Conclusion and questions for further research
- Chapter 11. Peripheral neuropathies
- Peripheral nervous system biology
- Clinical manifestation and diagnostic modalities in peripheral neuropathies
- Inherited neuropathies
- Immune-mediated neuropathies
- Other neuropathies
- Conclusion
- Questions for further research
- Chapter 12. Diabetes and cognitive dysfunction
- Diabetes mellitus
- Complications associated with diabetes
- Underlying mechanisms linking diabetes and Alzheimer's disease
- Animal models of diabetes and Alzheimer's disease
- Conclusion
- Chapter 13. Tumors of the nervous system
- Introduction
- Tumors of the nervous system
- Adult intraaxial brain and spinal cord tumors: glial tumors
- Primary CNS lymphoma
- Pediatric intraaxial brain tumors
- Tumors of the pineal region
- Tumors of the pituitary and sella
- Extraaxial tumors and peripheral nervous system tumors
- Autonomic nervous system tumors
- Future directions in neuro-oncology
- Studying brain tumors: cellular and animal models to translational research
- Concluding remarks
- Section III. Neurodegenerative diseases
- Chapter 14. Introduction to neurodegenerative disease section
- Chapter 15. Amyotrophic lateral sclerosis
- Introduction
- Diagnosis of amyotrophic lateral sclerosis
- Clinical characteristics of amyotrophic lateral sclerosis
- Natural history of amyotrophic lateral sclerosis
- Available treatments for amyotrophic lateral sclerosis
- Neurobiological basis of amyotrophic lateral sclerosis
- Model systems of amyotrophic lateral sclerosis
- Future directions
- Chapter 16. Parkinson disease and other synucleinopathies
- Introduction
- Clinical features of Parkinson disease
- Diagnosis of Parkinson disease
- Etiology of Parkinson disease: clues from epidemiology and genetics
- Treatment of Parkinson disease
- Questions for further research
- Conclusion
- Chapter 17. Huntington disease
- Overview of Huntington disease
- Animal models of Huntington disease
- Cellular models of Huntington disease
- Neuropathology of Huntington disease
- Pathogenesis of Huntington disease
- Treatment of Huntington disease
- Questions for further research
- Chapter 18. Repeat expansion disorders
- Introduction
- Pathophysiological mechanisms
- Therapeutics against repeat expansions
- Future of RED translational medicine
- Conclusion
- Chapter 19. Alzheimer diseases
- Introduction
- Clinical presentations and staging of the disease
- Neuropathological hallmarks of AD
- Genetics and molecular biology of AD
- Molecular biology of tau pathology
- Neuroinflammation as a driving force of neurodegeneration
- Development of mechanism-based therapeutics
- Development of diagnostic biomarkers of Alzheimer disease
- Summary and future directions
- Questions for further research
- Chapter 20. Frontotemporal lobar degeneration
- Introduction
- Neuropathology
- Clinical pathological correlations
- Structure and function of TDP-43, C9orf72, and GRN
- Therapeutic development for TDP-43 proteinopathies
- Structure and function of tau
- Therapeutic development for tauopathies
- Conclusions
- Chapter 21. Prion diseases
- Introduction
- Causes and pathogenesis of prion diseases
- Kuru
- Creutzfeldt–Jakob disease
- Variant Creutzfeldt–Jakob disease
- Gerstmann–Sträussler–Scheinker disease
- Laboratory tests
- Conclusion
- Questions for further research
- Chapter 22. Toxic/metabolic diseases of the nervous system
- Introduction
- Diet
- Alcohol
- Carbon monoxide
- Cyanide
- Metals
- Excitotoxins
- Organophosphates
- Cellular and animal models
- Conclusion
- Questions for future research
- Chapter 23. The role of inflammation in neurodegenerative diseases
- Introduction
- Peripheral inflammation in neurodegenerative diseases
- Microglia: the convergence point for promoting or compromising neuronal survival
- Neuroprotection mediated by neuronal-microglial signaling
- Neurotoxicity promoted by M1-activated microglia
- T lymphocytes—neuroprotection and neurotoxicity
- CD4+ T lymphocytes
- CD4+ T lymphocyte cytokines
- Parkinson's disease
- Alzheimer's disease
- Emerging cell-based and immunotherapies to mitigate inflammation in neurodegenerative diseases
- Concluding remarks
- Section IV. Acute insults to the central nervous system
- Chapter 24. Introduction: acute insults to the central nervous system
- Chapter 25. Spinal cord injury
- Introduction
- Conclusion
- Chapter 26. Traumatic brain injury
- Epidemiology and classifications
- Experimental models
- The pathology of TBI
- Acute responses after TBI
- Long-term consequences of TBI
- Blast TBI
- Future directions
- Chapter 27. Cerebrovascular disease—stroke
- Definition of stroke
- Brain lesions caused by cerebrovascular disease
- Vascular pathologies causing brain ischemia and hemorrhage
- Factors affecting tissue survival in patients with brain ischemia and infarction
- Death of cells in the CNS, and neuroprotective and reparative mechanisms
- Treatment of ischemic stroke in the acute period
- Animal models in acute ischemic stroke
- Questions for further research
- Section V. Infectious and immune-mediated diseases affecting the nervous system
- Chapter 28. Introduction
- Chapter 29. Infections and nervous system dysfunctions
- Inroduction
- Microbe–host cell interactions
- Immune responses to invading pathogens
- Invasion of pathogens in the nervous system
- Pathogens causing nervous system dysfunction
- Conclusions and questions for further research
- Chapter 30. Pathobiology of CNS human immunodeficiency virus infection
- Introduction
- Human immunodeficiency virus genetics and genomic organization of HIV-1
- Life cycle of the human immunodeficiency virus
- Establishment of human immunodeficiency virus infection
- Entry of human immunodeficiency virus into the CNS
- CNS human immunodeficiency virus infection by cell type
- CNS escape and viral latency
- Mechanisms of CNS injury
- CNS metabolic complications of human immunodeficiency virus infection
- Experimental models
- Clinical manifestations of CNS human immunodeficiency virus infection
- Effects of combination antiretroviral therapy on CNS human immunodeficiency virus pathology
- Mood disorders comorbid with HIV infection
- Mood disorders are more common in HIV-infected women
- The hypothalamic–pituitary–adrenal axis is impaired in MDD and HIV
- Conclusion and future challenges
- Chapter 31. Autoimmune and paraneoplastic neurological disorders
- Introduction
- The immune system
- Pathogenic mechanisms of neural antigen-specific autoimmunity
- Autoimmune and paraneoplastic neurological diseases
- Levels of the neuraxis affected by paraneoplastic and autoimmune syndromes
- Conclusion
- Future directions
- Chapter 32. Fibromyalgia and myalgic encephalomyelitis/chronic fatigue syndrome
- Introduction
- Fibromyalgia
- Chronic fatigue syndrome (now called myalgic encephalomyelitis/chronic fatigue syndrome or ME/CFS)
- Coexisting (comorbid) and overlapping syndromes of FM and ME/CFS
- Chapter 33. Multiple sclerosis and neuromyelitis optica spectrum disorders
- Introduction
- Etiology of multiple sclerosis
- Immune pathogenesis of multiple sclerosis
- Clinical features of multiple sclerosis
- Progressive multiple sclerosis as an unmet need
- Neuromyelitis optica spectrum disorders
- Disease models
- Treatment of multiple sclerosis
- Conclusion
- Questions for further research
- Section VI. Diseases of higher function
- Chapter 34. Introduction
- Chapter 35. Disorders of higher cortical function
- Introduction: from neuropsychology to mental structure
- Language disorders
- Memory disorders: amnesia
- Disorders of movement execution: apraxia
- Disorders of visual recognition: agnosia
- Disorders of attentional orientation and spatial representation: unilateral neglect
- Conscious awareness
- Future directions
- Chapter 36. Neurobioloy of sleep and circadian disorders
- Neurobiology of sleep and sleep disorders
- Chapter 37. Restless Legs Syndrome
- Introduction: a short historical perspective of Restless Legs Syndrome (RLS)
- Clinical definitions and diagnostic criteria
- Prevalence of RLS
- Idiopathic and secondary RLS
- Genome-wide association studies and origin of RLS
- Clinical pathophysiology of RLS
- Clinical disorders and comorbidities associated with RLS
- Periodic limb movements during sleep in RLS
- Altered spinal cord circuitry in RLS
- Treatment options for RLS—dopaminergics
- Alpha-2-delta ligands
- Iron therapies
- Opioids
- Cannabis
- Cellular and animal models of RLS
- Invertebrate models
- Vertebrate models
- Transgenic rodent models
- Nontransgenic rodent models
- Conclusion and questions for further research
- Chapter 38. Pain: from neurobiology to disease
- Introduction
- Terminology
- Factors that impact the emergence, prognosis, or severity of pain
- The neurobiology of pain
- Injury-induced plasticity
- Animal and cellular models used to study pain
- Hope for the magic bullet and why it does not yet exist
- Summary and conclusions
- Chapter 39. Migraine
- Introduction
- The migraine spectrum: an overview of clinical manifestations
- Peri-ictal clinical manifestations
- Comorbidity-related issues
- Migraine mechanisms
- Cortical and subcortical spreading depression
- Trigeminovascular system
- Genetics
- Pain signals from the dura: cascade and crescendo (central sensitization)
- The hyperexcitable brain: insights from photophobia, phonophobia, and osmophobia
- Autonomic features, including nausea and vomiting
- Mechanisms of comorbid depression
- Brainstem mechanisms in migraine, including pain modulation
- Migraine, stress, and stress circuits
- Brain changes associated with migraine attacks
- Measures of neurotransmitters showing hyperexcitable state
- Migraine chronification or transformation
- Placebo and migraine
- Migraine and allostatic load
- Migraine as a brain state–trait interaction
- Animal models of migraine
- Clinical insights from research
- Conclusion
- Questions for further research
- Chapter 40. Dystonia
- Introduction
- History of dystonia
- Clinical features and classification of dystonia
- Diagnostic challenges in dystonia
- Epidemiology of dystonia
- Adult-onset idiopathic focal/segmental isolated dystonia
- Genetic forms of dystonia
- Environmental risk factors in dystonia
- Pathophysiology of dystonia
- The brain network model and neuroimaging in dystonia
- Biochemical and molecular biology of dystonia
- Dystonia pathophysiology: implications for treatment
- Management of dystonia
- Surgical treatment of dystonia
- Unanswered questions
- Conclusion
- Chapter 41. Epilepsy
- Introduction
- Classification of the seizures and the epilepsies
- Mechanisms underlying seizures
- Mechanisms of epileptogenesis and epilepsy
- Treatment of epilepsy
- Summary
- Chapter 42. Stress
- Introduction
- Types of stress
- Definition of stress, allostasis, and allostatic load
- Response to stressors: protection and damage
- Positive effects of glucocorticoids on neuronal functions and structure
- Stress in the natural world
- Circadian disruption
- Key role of the brain in response to stress
- The brain as a target of stress
- Unanswered research questions
- Conclusion
- Chapter 43. Addictions
- Introduction and public health impact of the addictions
- Trajectory of addictions, and underlying neurobiology
- Animal models to study addictions
- Research techniques in humans
- Basic neurobiology of selected addictions
- The genetics of addictions
- Chapter 44. Fear-related anxiety disorders and posttraumatic stress disorder
- Introduction
- Classification of anxiety disorders
- Neuroanatomical basis of anxiety disorders
- Preclinical and animal models of anxiety
- Exploring the neurobiological basis of anxiety disorders in humans
- Clinical features and psychobiology of anxiety disorders
- Specific phobia
- Posttraumatic stress disorder
- Treatment for fear-related anxiety disorders and posttraumatic stress disorder
- Conclusions
- Chapter 45. Obsessive–compulsive disorder
- Introduction
- Epidemiology
- Clinical considerations
- Pathogenesis
- Treatment
- Obsessive–compulsive and related disorders (OCRDs)
- Pediatric populations
- Conclusion
- Research questions needing attention
- Chapter 46. The neurobiology of schizophrenia
- Clinical aspects of schizophrenia
- Neuroimaging
- Dysregulated neurotransmitter systems in schizophrenia
- Cholinergic neurotransmission
- Chapter 47. Depression and suicide
- Introduction
- Epidemiological observations in depression and suicide
- Pathogenesis of depression and suicide
- Genetic factors in depression and suicide
- Gene–environment interactions related to stress, depression, and suicide
- Neurotransmitter systems in major depression and suicidal behavior
- Cell plasticity and survival in depression and suicide
- Neuroanatomical changes in depression and suicide
- Resilience, depression, and suicide
- Cellular and animal models
- Treatment and its limitations
- Questions for further research
- Conclusions
- Chapter 48. Inflammation as a mediator of stress-related psychiatric disorders
- Interoception and mental health—focus on the immune system
- Sickness behaviors
- Immune signaling relevant to behavior
- Mechanisms from inflammation to behavior
- The microbiome as a source and mediator of inflammation
- Inflammation and mental health conditions
- Conclusion
- Chapter 49. Role of the gut microbiome in the pathophysiology of brain disorders
- Introduction
- The brain gut microbiome system
- The neuroendocrine communication channel
- The immune communication channel
- Diet, the gut microbiome, and brain health
- The brain gut microbiome system and brain disorders
- Dietary approaches in the treatment of brain gut microbiome disorders
- The role of preclinical studies in understanding and treatment of human brain gut disorders: animal models
- Conclusion
- Key questions for future research
- Section VII. Interface between biology and society in diseases of the nervous system
- Chapter 50. Introduction
- Chapter 51. Sex differences in neurological and psychiatric diseases
- The importance of comparing females and males
- Basic principles of sexual differentiation applied to disease
- Animal models to study sex-biasing factors that cause sex differences in disease mechanisms
- Sex differences in specific neurological and psychiatric diseases
- Prospectus
- Chapter 52. Integrative medicine in neurology
- Introduction
- Ayurveda
- Mindfulness
- Yoga
- Traditional Chinese medicine
- Acupuncture and acupressure
- Tai Chi
- Other forms of integrative medicine
- Cellular and animal models
- Questions for future research
- Conclusion
- Chapter 53. The impact of isolation on brain health
- The human being as a social animal
- Social isolation
- Early studies on biological effects of isolation on the brain during development
- Studies of the psychological consequences of social isolation and loneliness
- The psychological effects of solitary confinement
- Effects of isolation on the brain
- Effects of social isolation in animals
- List of unanswered questions
- Chapter 54. The neurobiology of aging
- Introduction
- Aging and behavior
- Aging and brain structure
- Aging and brain activity
- Genetics of aging
- Cellular and animal models
- Questions for future research
- Chapter 55. Palliative care in neurological disease
- Introduction
- Areas needing further research
- Chapter 56. Racial/ethnic health disparities
- Race as a biological or social construct?
- Racial disparities in health
- Stress, stressors and their role in health
- Understanding racial differences in health: a role for stress, socioeconomic status, and racism?
- Implications for further research
- Clinical implications
- Conclusion
- Important questions for further research
- Chapter 57. Advances in ethics for the neuroscience agenda
- Introduction
- Regulation and oversight
- Research with animals
- Sharing data, biosamples, and resources
- Incidental findings
- Neuroscience communication
- Conclusion
- Chapter 58. Burden of neurological disease
- Introduction
- Basic concepts in epidemiology
- Cerebrovascular disease
- Primary neoplasms
- Epilepsy and seizure disorders
- Dementia
- Parkinson's disease
- Multiple sclerosis
- Overview of neurological disorders
- Basis of burden of disease in developed and developing countries
- From communicable to noncommunicable
- The paths forward
- Research questions to be addressed
- Conclusion and future directions
- Index
- No. of pages: 1134
- Language: English
- Edition: 2
- Published: May 19, 2022
- Imprint: Academic Press
- Hardback ISBN: 9780323856546
- eBook ISBN: 9780323898256
MZ
Michael J. Zigmond
Affiliation: Professor of Neurology, Department of Neurology, University of Pittsburgh, Pennsylvania, U.S.A
Over the past year, Dr. Zigmond and his research team have continued their studies of cellular and animal models to examine Parkinson's disease (PD), which they believe is a multi-factorial disorder. A major focus of the lab is the role of intracellular signaling cascades in determining the viability of dopamine (DA) neurons. They hypothesize, for example, that trophic factors such as GDNF and oxidative stress can both stimulate intracellular survival cascades, including those involving MAP kinases. They further believe that endogenous trophic factor expression can be enhanced by exercise which in turn can be neuroprotective. And they have evidence that protection also can derive from acute exposure to low levels of a neurotoxin, a form of preconditioning. Last year their work included studies of the impact of oxidative stress induced by 6-hydroxydopamine (6-OHDA), a DA analogue that is concentrated in DA cells and rapidly breaks down to form reactive oxygen species. Results from these and other studies suggest that DA neurons react to stress by initiating a set of protective responses. Learning more about these responses may provide insights into new treatment modalities for PD.
In the coming year, Dr. Zigmond will continue to focus on understanding the strategies DA neurons use to reduce their vulnerability to intracellular stress. For example, studies are underway to determine if inhibition of trophic actor action or of kinase activation will block neuroprotection seen with exercise or GDNF or increase 6-OHDA toxicity. Some of these studies involve the preparation of molecular biological tools that maintain kinases in a constitutively or dominant negative state and/or localize a kinase to the cytoplasm or the nucleus. In addition, histochemical methods are being developed to quantify kinase levels in different cellular compartments of identified cells.
CW
Clayton A. Wiley
MC